Momenta Phama (MNTA) Reports Q3 Loss of $0.44/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. PINS
4. COIN
5. RDDT
6. FSLR
7. SYK
8. SBUX
9. SNDK
10. MA

Go back to Momenta Phama (MNTA) Reports Q3 Loss of $0.44/Share

Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

November 1, 2017 8:05 AM EDT

-- Ended third quarter with a strong cash position of $423M --

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2017 and provided a corporate update.

We continue to believe in the potential for the approval and launch of Glatopa® 40 mg in late 2017 or early 2018 and that there remains a meaningful market opportunity for this product in the U.S., said Craig A. Wheeler, President and Chief Executive Officer of Momenta... More